This term is going being thrown around much more in the media in days to come. TTPH pps is going to benefit.
Drug-resistant superbugs could cost the global economy as much as $100 trillion between now and 2050, a threat that warrants as much attention as climate change, according to a review led by economist Jim O’Neill.
Possibly if that lobster was dirty. Listening to this conference call, it sounds like the data presented at soon to be conference is highly anticipated and good for further gains.
If you guys want a great laugh look at the RCPT board. This stockssalesrigged guy said he was shorting nearly every day from 50's to 130. So if he is here I would take that as a good sign. The guy is either an absolute moron or does this for a living. He has also been doing the same thing on AGIO. Go big Blue.
Thanks I will buy it on the open. Have a good holiday. Truly an amazing year in biotech. We all have had great success, hope it continues into the new year.
Unsure, I just called around and no one had it or could get it for a while. That is just a small sample to draw definite conclusion from though.
"Here is why you want a piece of PTX.
Treximet demand has been there, the price is raised to over 1k a box. It is too small for ins. to catch on. Pernix will sell a lot right off the bat, it is now available. This revenue doesn't command a huge multiple but it is considerable amount. The silenor is a real sleeper and the revs are growing. It commands a bigger piece. You should buy it as it is so very cheap. Good luck all."
If you have a relationship with a RPH you can get prices that the pharmacies pay. Silenor is still actually cheaper than all other sleep aids, And also note that the vast majority of treximet users are not paying out of pockets. They are most likely using insurance. This type would only rise as more and more are covered due to obamacare. The increase in treximet demand is because it was not available from GSK for a few months so pretty much every pharmacy had to re-order from Pernix to restock. It is covered by most insurance, Good luck all.
As soon as the report came out on TTPH exploring sale. I bought a lot of cemp. I have owned ttph for quite a while. Pretty happy. I bought 2k of AKAO today to keep me interested, Been really enjoying this biotech rally. PTX boom coming, I hope so.
This is behaving similarly to others I have seen in weeks before a buyout. I doubt we see that kind of premium if a buyout occurs fairly soon. But I wouldn't be upset if it happened.
A couple small catalysts coming. You have the Otitis Media data coming this quarter and the Hylira wound gel word from FDA early 2105. Also I think they may have repackaged some treximet into this small carrying case for on-the-go use. Just a couple notes.
I think some money has shifted into a risk-on in biotech ie. my huge wins in AGIO, BLUE etc but it will most likely have some shift back into some revenue generators ie. PTX.
Take another look at BLUE. On the website look at pipeline, you will see the CELG collaboration is only with oncology. The big news is the Lentiglobin which is solely owned. I could see Blue getting into this 3 bil plus range as any news in sickle cell is worth a ton.